Browsing by Author "Mena, Álvaro"
Now showing items 1-20 of 33
-
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?
Pernas, Berta; Grandal, Marta; Pértega-Díaz, Sonia; Cañizares, Angelina; Castro-Iglesias, Ángeles; Mena, Álvaro; Rodríguez-Osorio, Iria; Tabernilla, Andrés; Pedreira, José D.; Poveda, Eva (Oxford University Press, 2015-12-24)[Abstract] Objectives. The objective of this study was to evaluate the prevalence of blips and risk of virological failure (VF) among HIV-infected patients with sustained virological suppression (HIV-RNA <50 copies/mL) on ... -
Cancer incidence in persons living with HIV
Meijide, Héctor; Mena, Álvaro; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Poveda, Eva (Oxford University Press para Infectious Diseases Society of America, 2016-11-14) -
Characterization of chronic HCV infection in Northwest Spain: impact of the treatment strategic plan of the Spanish National Health Service on HCV cure
Grandal, Marta; Pernas, Berta; Mariño, Ana; Álvarez, Hortensia; Tabernilla, Andrés; Castro-Iglesias, Ángeles; Mena, Álvaro; Delgado, Manuel; Pértega-Díaz, Sonia; Poveda, Eva (Wiley, 2017-03-14)[Abstract] The aim of the study was to characterize HCV infection in Northwest Spain and assess the impact of the Spanish Strategic Plan to cure HCV infection. Overall, 387 patients were included (60.9% HIV/HCV coinfected ... -
Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis
Mena, Álvaro; Vázquez-Rodríguez, Pilar; Castro-Iglesias, Ángeles; López, Soledad; Bello, Laura; Pedreira, José D. (Oxford, 2011-01-22) -
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy
Mena, Álvaro; Cid-Silva, Purificación; Dueñas, Carlos; Garcinuño, María Ángeles; Lorenzo, Juan Francisco; Margusino-Framiñán, Luis; Quiñones, Marina; Grande, Carmen; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles (Taylor & Francis, 2019-01-03)[Abstract] OBJECTIVES: Darunavir/ritonavir (DRV/r) in mono or dual therapy has proven efficacy in selected patients. The aim of this study was to evaluate the efficacy of switching from DRV/r to DRV/cobicistat (DRV/c) in ... -
Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ... -
Effectiveness and Safety of Direct‐Acting Antivirals in Hepatitis C Infected Patients With Mental Disorders: Results in Real Clinical Practice
Bobadilla-Pérez, Eva; Cid-Silva, Purificación; Rodríguez‐Sotelo, Alejandro; Yáñez‐Rubal, Juan C.; Mena, Álvaro; Suárez-López, Francisco; Prieto‐Pérez, Andrea; Giménez‐Arufe, Víctor; Delgado, Manuel; Sanclaudio‐Luhia, Ana I.; Martín‐Herranz, Isabel; Castro-Iglesias, Ángeles; Margusino-Framiñán, Luis (Willey Online Library, 2020-03-17)[Abstract] The aim of this study is to analyze the effectiveness and safety of direct‐acting antivirals (DAAs) in psychiatric patients with chronic hepatitis C (CHC). Secondary objectives included adherence and drug‐drug ... -
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Rotea-Salvo, Sandra; Mena, Álvaro; Suárez-López, Francisco; Vázquez-Rodríguez, Pilar; Delgado, Manuel; Sanclaudio-Luhia, Ana I.; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (BMJ Publishing Group, 2020-02-07)[Abstract] Objectives. Sofosbuvir/velpatasvir±ribavirin (SOF/VEL±RBV) and glecaprevir/pibrentasvir (GLE/PIB) are the drug combinations of choice for treating individuals with genotype 3 hepatitis C virus (G3-HCV) infection. ... -
Hemorragia digestiva alta secundaria a sarcoma de Kaposi gástrico y duodenal
Bello, Laura; Pardeiro Pértega, Remedios; Couto Wörner, Ignacio; Vázquez Rodríguez, Pilar; López-Calvo, Soledad; Castro-Iglesias, Ángeles; Mena, Álvaro; Alonso Aguirre, Pedro; Pedreira, José D. (Sociedad Española de Patología Digestiva, 2012) -
Impact of HCV infection in a HIV cohort followed over18 years: past and present
Mena, Álvaro; Rodríguez-Osorio, Iria; Meijide, Héctor; Castro-Iglesias, Ángeles; López-Calvo, Soledad; Vázquez Rodríguez, Pilar; Pernas, Berta; Grandal, Marta; Pedreira, José D. (Elsevier, 2015-04) -
Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin
Monje-Agudo, P.; Castro-Iglesias, Ángeles; Rivero-Juárez, A.; Martínez-Marcos, F.; Ortega-González, E.; Real, L.M.; Pernas, Berta; Merchante, N.; Cid-Silva, Purificación; Macías, J.; Merino, M.D.; Rivero, A.; Mena, Álvaro; Neukam, K.; Pineda, J.A. (Springer, 2015-07-09)[Abstract] It is commonly accepted that human immunodeficiency (HIV) coinfection negatively impacts on the rates of sustained virological response (SVR) to therapy with pegylated interferon plus ribavirin (PR). However, ... -
Increasing incidence of cancer in persons living with HIV coinfected with HCV: an additional impact of HCV infection?
Mena, Álvaro; Meijide, Héctor; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Pértega-Díaz, Sonia; Rodríguez-Martínez, Guillermo; Pernas, Berta; Baliñas, Josefa; Pedreira, José D.; Poveda, Eva (Elsevier, 2016) -
Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus
Margusino-Framiñán, Luis; Cid-Silva, Purificación; Giménez-Arufe, Víctor; Mondelo-García, Cristina; Fernández-Oliveira, Carla; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (BMJ, 2019-06-13)[Abstract] Objectives Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety. The objective ... -
Late HIV diagnosis but earlier antiretroviral treatment initiation in northwest Spain: impact of current treatment guidelines
Cid-Silva, Purificación; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Pernas, Berta; Mena, Álvaro; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Poveda, Eva (Sage, 2019-01-10)[Abstract] Background: Current HIV treatment guidelines recommend antiretroviral treatment (ART) initiation for all HIV-infected individuals regardless of CD4 count. This study evaluates the immunological and virological ... -
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis
Casado, José Luis; Mena, Álvaro; Bañón, S; Castro-Iglesias, Ángeles; Quereda, C; Moreno, A; Pedreira, José D.; Moreno, S (Wiley, 2015-06-30)[Abstract] Objectives. The aim of the study was to establish the risk of liver toxicity in HIV/hepatitis C virus (HCV)-coinfected patients receiving etravirine, according to the degree of liver fibrosis. Methods. A ... -
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
Rodríguez-Osorio, Iria; Mena, Álvaro; Meijide, Héctor; Morano, Luis; Delgado, Manuel; Cid-Silva, Purificación; Margusino-Framiñán, Luis; Pedreira, José D.; Castro-Iglesias, Ángeles (Plos ONE, 2019-06-03)[Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular ... -
Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV
Mena, Álvaro; Meijide, Héctor; Rodríguez-Osorio, Iria; Castro-Iglesias, Ángeles; Poveda, Eva (Wiley, 2017-02-23)[Abstract] Objectives. The aim of this study was to compare liver-related mortality and liver-related hospitalizations for persons living with HIV (PLWH) with and without hepatitis C virus (HCV) exposure, and to estimate ... -
Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Pernas, Berta; Grandal, Marta; Tabernilla, Andrés; Cid-Silva, Purificación; Pértega-Díaz, Sonia; Castro-Iglesias, Ángeles; Mena, Álvaro; Margusino-Framiñán, Luis; Pedreira, José D.; Poveda, Eva (Wiley, 2016-06-06)[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period ... -
Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers
Mena, Álvaro; Pedreira, José D.; Castro-Iglesias, Ángeles; López, Soledad; Vázquez-Rodríguez, Pilar; Poveda, Eva (Wiley, 2013-12-19)[Abstract] Background and Aim. There are few data of fibrosis development in chronic hepatitis B (CHB) patients classified as inactive carriers. The aim of this study is to determinate the prevalence of significant fibrosis ... -
Molecular characterization of HIV-1 infection in Northwest Spain (2009–2013): investigation of the subtype F outbreak
Paraskevis, Dimitrios; Kostaki, Evangelia; Beloukas, Apostolos; Cañizares, Angelina; Aguilera, Antonio; Rodríguez, Javier; Grandal, Marta; Pernas, Berta; Castro-Iglesias, Ángeles; Mena, Álvaro; Pedreira, José D.; Poveda, Eva (Elsevier, 2014-12-16)[Abstract] Background. HIV-1 subtype B is the predominant one in European regions several, while other subtypes and recombinants are also circulating with high prevalence. A sub-epidemic of subtype F with specific ...
